AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15197209 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and cisplatin
Number of subjects: 152
Study 15197209 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide/cisplatin
Number of subjects: 152
Study 11704447 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: anesthetic induction with halothane, maintenance with isoflurane, nitrous oxide (N2O), and oxygen (O2), LMA removed when child awakened
Number of subjects: 123
Study 11704447 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: anesthetic induction and maintenance as in Group 1, LMA removed while child anesthetized with age adjusted 2 minimum alveolar concentration (MAC) end‐tidal concentration of isoflurane
Number of subjects: 123
Study 11704447 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3: anesthetic induction and maintenance with sevoflurane, N2O, and O2, LMA removed when child awakened
Number of subjects: 123
Study 11704447 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 4: anesthetic induction and maintenance as in Group 3, but LMA removed while child anesthetized with age‐adjusted 2 MAC end‐tidal concentration of sevoflurane
Number of subjects: 123
Study 11704447 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 123
Study 9715923 — intervention group
Group type: EXPERIMENTAL
Intervention: Unvarying long-term home-based exercise program
Number of subjects: 124
Study 9715923 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 124
Study 8063980 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CB)
Number of subjects: 66
Study 8063980 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief psychodynamic therapy (PD)
Number of subjects: 66
Study 2736876 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate response to deep breathing
Number of subjects: 23
Study 2736876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-correlation test
Number of subjects: 23
Study 2736876 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva ratio
Number of subjects: 23
Study 2736876 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal results in deep breathing
Number of subjects: 23
Study 2736876 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal results in cross-correlation
Number of subjects: 23
Study 2736876 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal Valsalva ratio
Number of subjects: 23
Study 1256483 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Multiphasic Health Testing
Number of subjects: 574
Study 1256483 — intervention group
Group type: COMPARATOR
Intervention: Non-screened subjects
Number of subjects: 574
Study 31782814 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (BD; 256 μg) plus Montelukast (MNT; 10 mg) for 2 weeks
Number of subjects: 46
Study 31782814 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (BD; 256 μg) for 2 weeks
Number of subjects: 46
Study 30291868 — intervention group
Group type: EXPERIMENTAL
Intervention: MRE (MR elastography) estimated liver stiffness after 24 weeks of treatment with selonsertib
Number of subjects: 54
Study 30291868 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI-PDFF (MR imaging estimated proton density fat fraction) after 24 weeks of treatment with selonsertib
Number of subjects: 54
Study 28274214 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated child malnutrition prevention and treatment intervention package
Number of subjects: 1000
Study 28274214 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1000
Study 25052217 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dimenhydrinate (100 mg)
Number of subjects: 94
Study 25052217 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous piracetam (2000 mg)
Number of subjects: 94
Study 25052217 — intervention group
Group type: COMPARATOR
Intervention: Control group (not applicable)
Number of subjects: 94
Study 22750079 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 37
Study 22750079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 21700922 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism adaptation (PA) therapy - repetitive pointing with prism glasses inducing rightward optical shift, twice daily, 5 days per week, for 2 weeks.
Number of subjects: 38
Study 21700922 — intervention group
Group type: COMPARATOR
Intervention: Control group - similar pointing training with neutral glasses.
Number of subjects: 38
Study 18208636 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (10 microg/d)
Number of subjects: 0
Study 18208636 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (20 microg/d)
Number of subjects: 0
Study 18208636 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (10 and 20 microg/d)
Number of subjects: 0
Study 15936046 — intervention group
Group type: EXPERIMENTAL
Intervention: Salient local stimulus
Number of subjects: 0
Study 15936046 — intervention group
Group type: EXPERIMENTAL
Intervention: Small sized compound letters (where global shape was more salient)
Number of subjects: 0
Study 15936046 — intervention group
Group type: EXPERIMENTAL
Intervention: Salient irrelevant stimulus
Number of subjects: 0
Study 12972982 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg TRH
Number of subjects: 13
Study 12972982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 10966008 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab-treated patients undergoing emergency CABG
Number of subjects: 12
Study 9332904 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccadic eye movements in schizophrenic patients
Number of subjects: 46
Study 9332904 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccadic eye movements in fast-group patients
Number of subjects: 46
Study 9332904 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccadic eye movements in patients with hallucination and delusion symptoms
Number of subjects: 46
Study 9332904 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccadic eye movements in ordinary group patients
Number of subjects: 46
Study 9332904 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccadic eye movements in fast group patients
Number of subjects: 46
Study 9332904 — intervention group
Group type: COMPARATOR
Intervention: Saccadic eye movements in controls
Number of subjects: 46
Study 8252959 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotation (R) group
Number of subjects: 40
Study 8252959 — intervention group
Group type: COMPARATOR
Intervention: Nonrotation (NR) group
Number of subjects: 40
Study 3958225 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual administration of triazolam 0.5 mg
Number of subjects: 8
Study 3958225 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of triazolam 0.5 mg
Number of subjects: 8
Study 31302579 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat® (5 μg or 2.5 μg)
Number of subjects: 5165
Study 31302579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5165
Study 31302579 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat®
Number of subjects: 5165
Study 29562145 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 1096
Study 29562145 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 1096
Study 26670129 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic compression stocking (ECS) therapy for 2 years
Number of subjects: 300
Study 26670129 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic compression stocking (ECS) therapy with ability to put on independently
Number of subjects: 300
Study 26670129 — intervention group
Group type: EXPERIMENTAL
Intervention: ECS therapy
Number of subjects: 300
Study 25012415 — intervention group
Group type: EXPERIMENTAL
Intervention: CBASP (Cognitive Behavioral Analysis System of Psychotherapy)
Number of subjects: 10
Study 25012415 — intervention group
Group type: EXPERIMENTAL
Intervention: CBASP
Number of subjects: 10
Study 25012415 — intervention group
Group type: COMPARATOR
Intervention: Cingulum
Number of subjects: 10
Study 22395144 — intervention group
Group type: EXPERIMENTAL
Intervention: Omission of the bladder flap (n=127)
Number of subjects: 258
Study 22395144 — intervention group
Group type: COMPARATOR
Intervention: Creation of the bladder flap (n=131)
Number of subjects: 258
Study 20113765 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-weekly supervised pulmonary rehabilitation (n=15)
Number of subjects: 30
Study 20113765 — intervention group
Group type: COMPARATOR
Intervention: Twice-weekly supervised pulmonary rehabilitation (n=15)
Number of subjects: 30
Study 17108670 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine mouth spray (1 mg/actuation)
Number of subjects: 100
Study 17108670 — intervention group
Group type: COMPARATOR
Intervention: Nicotine gum (2 mg)
Number of subjects: 100
Study 17108670 — intervention group
Group type: COMPARATOR
Intervention: Nicotine inhaler
Number of subjects: 100
Study 15968231 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term family therapy (10 sessions over 6 months)
Number of subjects: 86
Study 15968231 — intervention group
Group type: COMPARATOR
Intervention: Long-term family therapy (20 sessions over 12 months)
Number of subjects: 86
Study 15968231 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term treatment for subjects with severe eating-related obsessive-compulsive features or from nonintact families
Number of subjects: 86
Study 12716087 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum at 15 mm Hg
Number of subjects: 0
Study 12716087 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum at 10 mm Hg
Number of subjects: 0
Study 12716087 — intervention group
Group type: COMPARATOR
Intervention: Recipients' kidneys
Number of subjects: 0
Study 10232739 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2-treated autologous bone marrow (BM)
Number of subjects: 36
Study 10232739 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2-treated peripheral stem cells (PSCs)
Number of subjects: 36
Study 10232739 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 treatment
Number of subjects: 36
Study 10232739 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose IL-2 by continuous i.v. infusion
Number of subjects: 36
Study 10232739 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance IL-2
Number of subjects: 36
Study 10232739 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2-treated patients with lymphoma
Number of subjects: 36
Study 10232739 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2-treated patients with acute leukemia
Number of subjects: 36
Study 10232739 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2-treated patients with myeloid leukemia
Number of subjects: 36
Study 8550853 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX) 1,000 mg/m2 intravenously over 24 h
Number of subjects: 150
Study 8550853 — intervention group
Group type: COMPARATOR
Intervention: Lower-dose methotrexate (LDMTX) 30 mg/m2 by mouth every 6 h x 6
Number of subjects: 150
Study 8550853 — intervention group
Group type: EXPERIMENTAL
Intervention: HDMTX
Number of subjects: 150
Study 8550853 — intervention group
Group type: COMPARATOR
Intervention: LDMTX
Number of subjects: 150
Study 1987712 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological stress monitoring and intervention (GHQ greater than or equal to 5)
Number of subjects: 461
Study 1987712 — intervention group
Group type: COMPARATOR
Intervention: Routine medical care after discharge (Control)
Number of subjects: 461
Study 6122111 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diazoxide
Number of subjects: 126
Study 6122111 — intervention group
Group type: EXPERIMENTAL
Intervention: Minoxidil
Number of subjects: 126
Study 6122111 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 126
Study 6122111 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy (diuretic + beta‐adrenoceptor blocker + hydralazine + prazosin)
Number of subjects: 126
Study 6122111 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional stepped-care regimen)
Number of subjects: 126
Study 6122111 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment outcomes
Number of subjects: 126
Study 30288819 — intervention group
Group type: EXPERIMENTAL
Intervention: PacBio full-length cDNA sequencing integrated with RNA-seq reads
Number of subjects: 11733
Study 29776672 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose photodynamic therapy (PDT)
Number of subjects: 179
Study 29776672 — intervention group
Group type: COMPARATOR
Intervention: High-density subthreshold micropulse laser (HSML)
Number of subjects: 179
Study 26960195 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) with deep needling at BL33 and BL35
Number of subjects: 80
Study 26960195 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture (sham EA) with non-penetrating needling at sham acupoints
Number of subjects: 80
Study 26960195 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 80
Study 26960195 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture (sham EA)
Number of subjects: 80
Study 24562449 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine treatment
Number of subjects: 160
Study 24562449 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 160
Study 22209386 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxycodone 15 mg/70 kg
Number of subjects: 20
Study 22209386 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxycodone 30 mg/70 kg
Number of subjects: 20
Study 22209386 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor testing (CPT)
Number of subjects: 20
Study 22209386 — intervention group
Group type: COMPARATOR
Intervention: Warm water control
Number of subjects: 20
Study 19995475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.54 mg/kg within 30 min)
Number of subjects: 20
Study 19995475 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17555820 — intervention group
Group type: EXPERIMENTAL
Intervention: 1CU IOL
Number of subjects: 79
Study 17555820 — intervention group
Group type: EXPERIMENTAL
Intervention: AT‐45 IOL
Number of subjects: 79
Study 17555820 — intervention group
Group type: COMPARATOR
Intervention: Monofocal IOL
Number of subjects: 79
Study 15805380 — intervention group
Group type: EXPERIMENTAL
Intervention: Lucinactant
Number of subjects: 1294
Study 15805380 — intervention group
Group type: COMPARATOR
Intervention: Colfosceril palmitate
Number of subjects: 1294
Study 15805380 — intervention group
Group type: COMPARATOR
Intervention: Beractant
Number of subjects: 1294
Study 12510415 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily
Number of subjects: 40
Study 12510415 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 400 mg twice a day
Number of subjects: 40
Study 9856708 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic lidocaine (2 mg/kg bolus followed by 2 mg x kg(‐1) x h(‐1) infusion for 50 min)
Number of subjects: 12
Study 9856708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous regional anesthesia with lidocaine (40 ml, 0.05%)
Number of subjects: 12
Study 9856708 — intervention group
Group type: COMPARATOR
Intervention: Control with NaCl (0.9%)
Number of subjects: 12
Study 9856708 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (systemic and regional lidocaine)
Number of subjects: 12
Study 7697578 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief physician interventions
Number of subjects: 11
Study 7697578 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 11
Study 2258248 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg oral dose
Number of subjects: 5
Study 2258248 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 553663 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine inhalation
Number of subjects: 0
Study 30880731 — intervention group
Group type: EXPERIMENTAL
Intervention: No scalpel vasectomy (NSV) awareness and acceptance
Number of subjects: 48
Study 28739542 — intervention group
Group type: EXPERIMENTAL
Intervention: Math intervention
Number of subjects: 28
Study 28739542 — intervention group
Group type: EXPERIMENTAL
Intervention: Spelling intervention
Number of subjects: 28
Study 28739542 — intervention group
Group type: COMPARATOR
Intervention: Active learning (general)
Number of subjects: 28
Study 25044531 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP+AZM (500 mg oral delivery × 3 days)
Number of subjects: 70
Study 25044531 — intervention group
Group type: COMPARATOR
Intervention: SRP+Placebo (OD × 3 days)
Number of subjects: 70
Study 24366433 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotonic 0.18% sodium hyaluronate artificial tears
Number of subjects: 50
Study 24366433 — intervention group
Group type: COMPARATOR
Intervention: Sterile 0.9% sodium chloride solution (control)
Number of subjects: 50
Study 23083066 — intervention group
Group type: EXPERIMENTAL
Intervention: CHMP 3×2 tablets per day
Number of subjects: 351
Study 23083066 — intervention group
Group type: EXPERIMENTAL
Intervention: CHMP 2×2 tablets per day
Number of subjects: 351
Study 23083066 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3×2 tablets per day)
Number of subjects: 351
Study 19129308 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi group (n = 74)
Number of subjects: 136
Study 19129308 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 62)
Number of subjects: 136
Study 17558914 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic endoscope imaging (MEI) during colonoscopy
Number of subjects: 419
Study 17558914 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy without MEI
Number of subjects: 419
Study 17558914 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic endoscope imaging (MEI) during colonoscopy by experienced colonoscopists
Number of subjects: 419
Study 17558914 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy without MEI by experienced colonoscopists
Number of subjects: 419
Study 14767083 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI with spacer (400 micrograms salbutamol)
Number of subjects: 153
Study 14767083 — intervention group
Group type: COMPARATOR
Intervention: DPI (rotahaler, 400 micrograms salbutamol)
Number of subjects: 153
Study 11734733 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated trivalent influenza vaccine
Number of subjects: 791
Study 11734733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-adapted vaccine
Number of subjects: 791
Study 11734733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 791
Study 9399001 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine sufferers
Number of subjects: 41
Study 9399001 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine sufferers with stronger odour perception during attacks
Number of subjects: 41
Study 9399001 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 41
Study 7522282 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5‐10 mg, once daily)
Number of subjects: 461
Study 7522282 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10‐40 mg, once daily)
Number of subjects: 461
Study 3439796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) treatment
Number of subjects: 35
Study 3439796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 29069415 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccines (PCVs)
Number of subjects: 5224
Study 26565716 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine (0.05%) gel
Number of subjects: 61
Study 26565716 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine (1.25 mg) film
Number of subjects: 61
Study 26565716 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 61
Study 26565716 — intervention group
Group type: COMPARATOR
Intervention: Placebo film
Number of subjects: 61
Study 25948671 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of SFA intake (>31.28 g/d)
Number of subjects: 1469
Study 25948671 — intervention group
Group type: COMPARATOR
Intervention: Lowest quartile of SFA intake (<17.39 g/d)
Number of subjects: 1469
Study 25948671 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SFA intake
Number of subjects: 1469
Study 23994919 — intervention group
Group type: EXPERIMENTAL
Intervention: Reosorbilact (200-400 ml intravenously for 20 days)
Number of subjects: 0
Study 20338811 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide (CY)
Number of subjects: 52
Study 18218110 — intervention group
Group type: EXPERIMENTAL
Intervention: PRAFAB questionnaire (5-item)
Number of subjects: 279
Study 12804135 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmid DNA encoding gp100 administered intradermally (n = 10)
Number of subjects: 22
Study 12804135 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasmid DNA encoding gp100 administered intramuscularly (n = 12)
Number of subjects: 22
Study 9799058 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum of parent compound and metabolite
Number of subjects: 4
Study 9799058 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent compound
Number of subjects: 4
Study 9799058 — intervention group
Group type: EXPERIMENTAL
Intervention: Each metabolite
Number of subjects: 4
Study 7617607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 16
Study 7617607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2520143 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg/day)
Number of subjects: 67
Study 2520143 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 405412 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable isosorbide dinitrate (I)
Number of subjects: 12
Study 405412 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (N)
Number of subjects: 12
Study 405412 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 12